Charles River Laboratories (CRL)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 7.74% | 26.69% | 43.67% | 59.95% | 60.96% | 63.36% | 63.29% | 64.22% | 79.85% | 79.89% | 80.27% | 78.83% | 78.05% | 67.94% | 58.40% | 47.32% | 37.54% | 37.53% | 36.80% | 37.39% |
| Operating profit margin | 5.56% | 12.97% | 13.85% | 14.15% | 15.10% | 15.02% | 15.08% | 15.85% | 15.85% | 17.40% | 18.05% | 17.05% | 17.05% | 16.38% | 16.48% | 15.77% | 15.13% | 14.95% | 13.81% | 14.06% |
| Pretax margin | 2.20% | 12.64% | 13.20% | 13.35% | 14.08% | 14.18% | 14.48% | 15.09% | 15.02% | 14.10% | 14.51% | 14.36% | 13.67% | 14.49% | 15.66% | 15.51% | 15.60% | 13.77% | 11.75% | 10.92% |
| Net profit margin | 0.54% | 10.41% | 10.88% | 10.93% | 11.61% | 11.01% | 11.27% | 11.74% | 11.84% | 11.51% | 12.04% | 11.72% | 11.30% | 11.90% | 12.48% | 12.80% | 12.74% | 10.92% | 10.06% | 9.27% |
Charles River Laboratories has shown fluctuations in its profitability ratios over the years.
- Gross Profit Margin: The company's gross profit margin has shown a general increasing trend from March 31, 2020, to June 30, 2022, reaching a peak of 80.27%. However, there was a decline in the margin in the following quarters, dropping to 26.69% on September 30, 2024.
- Operating Profit Margin: The operating profit margin has also experienced fluctuations, with a gradual increase until June 30, 2022, where it peaked at 18.05%. Subsequently, the margin decreased to 5.56% by December 31, 2024.
- Pretax Margin: The pretax margin varied over time, with peaks observed in December 31, 2020, at 15.60% and December 31, 2022, at 15.02%. However, there was a significant decline in the margin to 2.20% by December 31, 2024.
- Net Profit Margin: The net profit margin showed fluctuations, with the highest point at 12.80% on March 31, 2021. However, it declined to 0.54% on December 31, 2024, indicating a significant decrease in profitability.
Overall, the trends in profitability ratios suggest that Charles River Laboratories has experienced fluctuations in its profitability over the periods analyzed, with some quarters showing strong performance while others show signs of decline. It is important for the company to closely monitor and address the factors influencing these fluctuations to ensure sustained profitability in the future.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 3.02% | 6.60% | 7.07% | 7.06% | 7.53% | 8.52% | 8.33% | 8.70% | 8.56% | 8.94% | 8.83% | 8.69% | 8.40% | 7.74% | 7.78% | 7.96% | 7.88% | 7.91% | 7.11% | 7.22% |
| Return on assets (ROA) | 0.29% | 5.29% | 5.55% | 5.45% | 5.79% | 6.24% | 6.23% | 6.45% | 6.40% | 5.91% | 5.89% | 5.97% | 5.57% | 5.62% | 5.89% | 6.46% | 6.63% | 5.78% | 5.18% | 4.76% |
| Return on total capital | 6.76% | 16.97% | 18.01% | 18.68% | 19.80% | 22.68% | 22.67% | 23.24% | 22.71% | 21.73% | 21.74% | 21.88% | 21.57% | 23.84% | 25.66% | 25.45% | 25.18% | 24.13% | 21.77% | 21.65% |
| Return on equity (ROE) | 0.64% | 11.20% | 11.86% | 12.21% | 13.20% | 14.37% | 14.89% | 15.97% | 16.34% | 16.61% | 16.74% | 16.19% | 15.42% | 16.34% | 17.08% | 17.17% | 17.23% | 15.89% | 15.48% | 14.99% |
Charles River Laboratories' profitability ratios have shown varying trends over the past few years.
The Operating Return on Assets (Operating ROA) has generally been increasing from 7.22% in March 2020 to 8.56% in December 2022, before experiencing a slight decline to 7.53% by December 2023. Notably, the ratio improved to 8.70% by March 2024, indicating the company's ability to generate operating profits from its assets.
The Return on Assets (ROA) also generally exhibited an upward trend, starting at 4.76% in March 2020, reaching a peak of 6.63% in December 2020, and then fluctuating slightly before dropping notably to 0.29% by December 2024. This decline in ROA suggests that the company's net income generated from its total assets decreased significantly towards the end of the analyzed period.
In terms of Return on Total Capital, the ratios fluctuated within a narrower range compared to the other profitability metrics. The ratio ranged from 16.97% in September 2024 to a peak of 25.66% in June 2021. However, there was a noticeable decrease to 6.76% by December 2024, indicating a decline in the company's ability to generate returns from its total capital towards the end of the period.
Return on Equity (ROE) followed a similar pattern to ROA, with a general upward trajectory before decreasing towards the end of the period. The ROE reached a peak of 17.23% in December 2020 before dropping to 0.64% by December 2024. This significant decline in ROE suggests a reduction in profitability relative to shareholders' equity.
Overall, while Charles River Laboratories demonstrated improvements in some profitability ratios over the analyzed period, there were also notable declines in others, signaling potential challenges in generating returns from assets, total capital, and equity in the latter part of the period.